Low impact
00.10.43f, Reimbursement for the Administration of Drugs, Substances, and/or Biologic Agents
Independence Blue Cross·Identified Jun 19, 2026
HCPCS G0138 is officially defined as "Intravenous infusion of cipaglucosidase alfa-atga, including provider/supplier acquisition and clinical supervision of oral administration of miglustat in preparation of receipt of cipaglucosidase alfa-atga." HCPCS G0138 is referenced in 1 tracked payer policy change from Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS G0138 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.